Search results for "Anti-Arrhythmia Agent"

showing 10 items of 35 documents

Polymorphism and solvates of flecainide base

2013

Flecainide base is pharmaceutically active substance used for production of flecainide acetate which is known in market as Tambacor, Almarytm, Apocard, Ecrinal or Flecaine. It is determined that flecainide base forms four polymorphic forms abbreviated as Ib, IIb, IIIb and IVb. Flecainide base form Ib is thermodynamically stable form at laboratory temperature while form IIIb is stable at higher temperatures. Flecainide form Ib absorbs water in its structure between layers and forms non-stoichiometric hydrate. Flecainide base binds with organic solvents and form monosolvates. Flecainide base form Ib crystallizes in orthorhombic crystals with lattice parameters a = 27.88 Å, b = 13.78 Å, c = 9.…

Voltage-Gated Sodium Channel BlockersFlecainideChemistryWaterPharmaceutical ScienceGeneral MedicineFlecainide Acetatelaw.inventionCrystallographyX-Ray DiffractionPolymorphism (materials science)lawX-ray crystallographymedicineThermodynamicsMoleculeOrthorhombic crystal systemCrystallizationCrystallizationHydrateAnti-Arrhythmia AgentsFlecainidemedicine.drugPharmaceutical Development and Technology
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo

2003

In the present study we examined the metabolism of [(14)C]propafenone (P) and [(14)C]verapamil (V) using cryopreserved human, dog (Beagle), rat (Sprague-Dawley) and mouse (NMRI) hepatocytes. The percentage ratios of the metabolites were identified after extraction by HPLC with UV and radioactivity detection. Phase-II metabolites were cleaved using beta-glucuronidase. Metabolism of the drugs by cryopreserved hepatocytes was compared with that in the respective species in vivo. All phase-I and -II metabolites known from in vivo experiments: 5-hydroxy-P (5-OH-P); 4'-hydroxy-P (4'-OH-P); N-despropyl-P (NdesP) and the respective glucuronides, were identified after incubation with cryopreserved h…

Time FactorsPropafenoneIn Vitro TechniquesPharmacologyCryopreservationRats Sprague-DawleyHydroxylationMicechemistry.chemical_compoundDogsGlucuronidesPropafenoneSpecies SpecificityIn vivomedicineAnimalsHumansIncubationAgedCryopreservationPharmacologyChemistryGeneral MedicineMetabolismMiddle AgedIn vitroRatsVerapamilBiochemistryHepatocytesVerapamilAnti-Arrhythmia Agentsmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

[Effect of flecainide on longitudinal and transverse conduction velocities in ventricular myocardium. An experimental study].

2007

It is known that the effect of flecainide on longitudinal and transverse ventricular conduction velocities depends on the coupling interval. If this is so, whether the longitudinal or transverse direction is predominantly affected could depend on the magnitude of the coupling interval. In order to investigate this hypothesis, we studied the effect of flecainide, 1 micromol/L, on conduction velocities in excised heart preparations from 11 rabbits using a basal cycle length of 250 ms and inserting two extrastimuli at a decreasing coupling interval. Flecainide significantly reduced both conduction velocities. However, the effect increased as the coupling interval decreased for only the longitu…

medicine.medical_specialtyFlecainidebusiness.industryHeartGeneral MedicineThermal conductionNerve conduction velocityVentricular myocardiumCoupling (electronics)Transverse planeHeart Conduction SystemInternal medicinemedicineCardiologyAnimalsVentricular FunctionRabbitsbusinessCycle lengthFlecainideTransverse directionAnti-Arrhythmia Agentsmedicine.drugRevista espanola de cardiologia
researchProduct

Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success.

2015

Background— In the meantime, catheter ablation is widely used for the treatment of persistent atrial fibrillation (AF). There is a paucity of data about long-term outcomes. This study evaluates (1) 5-year single and multiple procedure success and (2) prognostic factors for arrhythmia recurrences after catheter ablation of persistent AF using the stepwise approach aiming at AF termination. Methods and Results— A total of 549 patients with persistent AF underwent de novo catheter ablation using the stepwise approach (2007–2009). A total of 493 patients were included (Holter ECGs ≥every 6 months). Mean follow-up was 59±16 months with 2.1±1.1 procedures per patient. Single and multiple procedu…

AdultMaleReoperationmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentCatheter ablationKaplan-Meier EstimateDisease-Free SurvivalYoung AdultSex FactorsHeart RatePredictive Value of TestsRecurrenceRisk FactorsPhysiology (medical)Internal medicineHeart rateAtrial FibrillationmedicineTachycardia SupraventricularHumans610 Medicine & healthAgedRetrospective StudiesAged 80 and overbusiness.industryAtrial fibrillationRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryTreatment OutcomeAtrial FlutterPredictive value of testsPersistent atrial fibrillationMultivariate AnalysisCardiologyCatheter AblationElectrocardiography AmbulatoryFemaleCardiology and Cardiovascular MedicinebusinessStepwise approachAnti-Arrhythmia AgentsAtrial flutterFollow-Up StudiesCirculation. Arrhythmia and electrophysiology
researchProduct

Iatrogenic pulmonary lesions.

2018

Treatment of patients often includes the administration of medications and sometimes radiation. While the intent is to treat an underlying condition, in some cases, adverse effects occur due to these agents. Most of these adverse effects are mild, however, some can be severe and life-threatening. Furthermore, while these effects are often reversible upon cessation of exposure, especially if the inciting agent is recognized and withdrawn early, others might be permanent or even progressing. Most common histopathologic findings in drug-induced interstitial lung disease include nonspecific interstitial pneumonia (cellular and/or fibrotic), organizing pneumonia with or without bronchiolitis, eo…

medicine.medical_specialtyPathologyDrug-Related Side Effects and Adverse ReactionsPolymersIatrogenic DiseaseAmiodaroneAntineoplastic Agents030204 cardiovascular system & hematologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineEarly Medical InterventionmedicineEosinophilic pneumoniaHumansImmunologic FactorsIntensive care medicineDiffuse alveolar damageAdverse effectLungLungRadiotherapybusiness.industryInterstitial lung diseasePulmonary edemamedicine.diseasemedicine.anatomical_structureEquipment and SuppliesNitrofurantoin030220 oncology & carcinogenesisPulmonary hemorrhagebusinessLung Diseases InterstitialAnti-Arrhythmia AgentsHydrophobic and Hydrophilic InteractionsHypersensitivity pneumonitisSeminars in diagnostic pathology
researchProduct

Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation

2018

Aim The impact of rate and rhythm control strategies on outcomes in patients with atrial fibrillation (AF) remains controversial. Our aims were: to report use of rate and rhythm control strategies in European patients from the EURObservational Research Program AF General Pilot Registry. Secondly, to evaluate outcomes according to assigned strategies. ........................................................................................................................................................... Methods and results Use of pure rate and rhythm control agents was described according to European regions. 1-year follow-up data were reported. Among rate control strategies, beta-blockers …

MaleTime FactorsRate controlAction PotentialsPilot Projects030204 cardiovascular system & hematologyAmiodaroneAction Potentials/drug effectsHeart Conduction System/drug effectsCardiologists0302 clinical medicineHeart RateRisk FactorsCause of DeathAtrial Fibrillation030212 general & internal medicineRegistriesPractice Patterns Physicians'Cause of deathAged 80 and overAll-cause death; Atrial fibrillation; Major adverse events; Rate control; Registry; Rhythm controlHeart Rate/drug effectsAtrial fibrillationMiddle AgedEuropeTreatment OutcomeCohortCardiologyHealthcare Disparities/trendsRhythm controlFemaleCardiology and Cardiovascular MedicineAnti-Arrhythmia AgentsCardiologists/trendsmedicine.drugmedicine.medical_specialtyMajor adverse eventsRegistryAll-cause deathAnti-Arrhythmia Agents/adverse effectsEurope/epidemiology03 medical and health sciencesHeart Conduction SystemPhysiology (medical)Internal medicineHeart ratemedicineAtrial Fibrillation/diagnosisHumansHealthcare DisparitiesAdverse effectAgedbusiness.industryProportional hazards modelmedicine.diseaseAtrial fibrillationPractice Patterns Physicians'/trendsAtrial fibrillation • Rate control • Rhythm control • Major adverse events • All-cause death • RegistryPropensity score matchingbusiness
researchProduct

MitoKATP-channel opener protects against neuronal death in rat venous ischemia.

2005

OBJECTIVE: Mitochondrial adenosine triphosphate-dependent potassium (mitoK ATP ) channels are present in the brain, and several reports have shown their neuroprotective, preconditioning effect against an ischemic insult. The role of mitoK ATP channels in the penumbra area has not been studied thoroughly. In a model of venous ischemia, widespread penumbra-like low flow areas are created, which are susceptible to cortical spreading depression. Thus, we studied effects of mitoK ATP channels on infarct size in this model. METHODS: Male Wistar rats were subjected to two-vein occlusion by photochemical thrombosis of two adjacent cortical veins combined with KCI-induced cortical spreading depressi…

Brain InfarctionMalemedicine.medical_specialtyPotassium ChannelsPhotochemistryIschemiaBrain EdemaPotassium ChlorideIschemiaInternal medicinemedicineDiazoxideLaser-Doppler FlowmetryAnimalsChannel blockerDrug InteractionsRats WistarNeuronsAnalysis of VarianceCell Deathbusiness.industryPenumbraCortical Spreading DepressionDiazoxidemedicine.diseaseCerebral VeinsPotassium channelRatsTolerance inductionDisease Models AnimalNeuroprotective AgentsCerebral blood flowRegional Blood FlowAnesthesiaCortical spreading depressionCardiologySurgeryNeurology (clinical)businessHydroxy AcidsAnti-Arrhythmia AgentsDecanoic Acidsmedicine.drugNeurosurgery
researchProduct

CaMKII inhibition reduces electrical activation heterogeneities caused by mechanical stretch in the myocardium

2020

Abstract Introduction Ca2+/calmodulin-dependant protein kinase II (CaMKII) activity in cardiomyocytes plays a crucial role in their contractility. Increased CaMKII signalling has been associated with mechanical stretch, often caused in the border zone of myocardial infarction. CaMKII upregulation causes a mishandling of intracellular calcium, a precursor of multiple pro-arrhythmic mechanisms, such as early afterdepolarisations. Purpose In this study, we aim to quantify the effects of KN-93 -a CaMKII inhibitor- on wave dynamics, in order to investigate its effectiveness as an anti-arrhythmic agent. Methods An isolated Langendorff model was constructed based on rabbit hearts (n=18) and poster…

Calmodulinbiologybusiness.industrychemistry.chemical_elementCardiac arrhythmiaTorsades de pointesCalciumPharmacologymedicine.diseasechemistryCa2+/calmodulin-dependent protein kinaseHeart failurebiology.proteinmedicineSignal transductionCardiology and Cardiovascular MedicinebusinessAnti-Arrhythmia AgentsEuropean Heart Journal
researchProduct

Biowaiver monographs for immediate release solid oral dosage forms: quinidine sulfate.

2009

Literature data are reviewed relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of new multisource and reformulated immediate release (IR) solid oral dosage forms containing quinidine sulfate. Quinidine sulfate's solubility and permeability, its therapeutic use and index, pharmacokinetics, excipient interactions and reported BE/bioavailability (BA) problems were taken into consideration. The available data are not fully conclusive, but do suggest that quinidine sulfate is highly soluble and moderately to highly permeable and would likely be assigned to BCS Class I (or at worst BCS III). In view of the inconclusiveness of the data and, more imp…

QuinidineDosage FormsChemistryBiopharmaceuticsPharmaceutical ScienceExcipientAdministration OralBiological AvailabilityPharmacologyBioequivalenceQuinidineDosage formPermeabilityBioavailabilityExcipientsAntimalarialsPharmacokineticsQuinidine SulfateSolubilityTherapeutic EquivalencymedicineHumansAnti-Arrhythmia AgentsDrug Approvalmedicine.drugJournal of pharmaceutical sciences
researchProduct